Chimeric Antigen Receptor (CAR)-T cell therapies are treatments in which a patient's T cells are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added in the laboratory.
In multiple myeloma, currently approved CAR-T therapies are targeted against B-cell maturation antigen (BCMA). Although research suggests that CD229 might be a good future target — potentially providing longer-lasting responses.